产品: Cytochrome P450 7A1 抗体
货号: DF2612
描述: Rabbit polyclonal antibody to Cytochrome P450 7A1
应用: WB IHC IF/ICC
文献验证: WB, IHC
反应: Human, Mouse, Rat
预测: Pig, Horse, Rabbit, Dog
蛋白号: P22680
RRID: AB_2839818

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Cytochrome P450 7A1 Antibody detects endogenous levels of total Cytochrome P450 7A1.
RRID:
AB_2839818
引用格式: Affinity Biosciences Cat# DF2612, RRID:AB_2839818.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Cholesterol 7 alpha hydroxylase; Cholesterol 7 alpha monooxygenase; Cholesterol 7-alpha-hydroxylase; Cholesterol 7-alpha-monooxygenase; CP7A; CP7A1_HUMAN; CYP 7; CYP7; CYP7A1; CYPVII; Cytochrome P450 7A1; Cytochrome P450, family 7, subfamily A, polypeptide 1; Cytochrome P450, subfamily VIIA (cholesterol 7 alpha monooxygenase),; Cytochrome P450, subfamily VIIA (cholesterol 7 alpha-monooxygenase), polypeptide 1; MGC126826; MGC138389;

抗原和靶标

免疫原:

A synthesized peptide derived from human Cytochrome P450 7A1, corresponding to a region within the internal amino acids.

基因/基因ID:
描述:
Catalyzes a rate-limiting step in cholesterol catabolism and bile acid biosynthesis by introducing a hydrophilic moiety at position 7 of cholesterol. Important for cholesterol homeostasis.

研究领域

· Metabolism > Lipid metabolism > Primary bile acid biosynthesis.

· Metabolism > Lipid metabolism > Steroid hormone biosynthesis.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Digestive system > Cholesterol metabolism.

文献引用

1). Geniposidic Acid Targeting FXR "S332 and H447" Mediated Conformational Change to Upregulate CYPs and miR-19a-3p to Ameliorate Drug-Induced Liver Injury. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 (PubMed: 39998442) [IF=15.1]

Application: WB    Species: Mouse    Sample:

Figure 4 GPA promotes cholesterol metabolism by accelerating the synthesis and efflux of primary bile acids. A) Dynamic distribution map of differences in lipid content. B) Differential lipid KEGG classification map. C) Differential lipid KEGG enrichment map. D) Primary free bile acid content in mouse liver (n = 6). E) Mouse liver primary conjugated bile acid content (n = 6). F) Mouse liver secondary conjugated bile acid content (n = 6). G) Secondary free bile acid content in mouse liver (n = 6). H,I) The mRNA and protein expression of hepatic BSEP, CYP7A1, CYP8B1, CYP27A1, and CYP7B1 in TP chronic DILI mice treated with GPA (n = 6). All mRNA levels were measured by qPCR, normalized to GAPDH. J,K) The mRNA and protein expression of hepatic BSEP, CYP7A1, CYP8B1, CYP27A1, and CYP7B1 in APAP acute DILI mice treated with GPA (n = 6). All mRNA levels were measured by qPCR, normalized to GAPDH. L,M) The mRNA and protein expression of hepatic BSEP, CYP7A1, CYP8B1, CYP27A1, and CYP7B1 in TP chronic DILI mice treated with GPA (n = 6). All mRNA levels were measured by qPCR, normalized to GAPDH. N) Summary of upregulating CYPs-transporter-mediated primary bile acid synthesis and transport of GPA treatment of acute and chronic DILI. All data are presented as means ± SD. Compared with control group, *P < 0.05, **P < 0.01, ***P < 0.001. Compared with model group, #P < 0.05, ##P < 0.01, ###P < 0.001. All data are via one-way analysis of variance (ANOVA).

2). Geniposidic Acid Targeting FXR "S332 and H447" Mediated Conformational Change to Upregulate CYPs and miR-19a-3p to Ameliorate Drug-Induced Liver Injury. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 (PubMed: 39998442) [IF=14.3]

3). Resveratrol Modulates the Redox Response and Bile Acid Metabolism to Maintain the Cholesterol Homeostasis in Fish Megalobrama amblycephala Offered a High-Carbohydrate Diet. Antioxidants (Basel, Switzerland), 2023 (PubMed: 36670983) [IF=7.0]

4). Disruption of cholesterol homeostasis triggers NLRP3-cGAS-STING axis-dependent hepatic fibrosis and honokiol intervention effects. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2025 (PubMed: 40449452) [IF=6.7]

5). NRF2 and FXR dual signaling pathways cooperatively regulate the effects of oleanolic acid on cholestatic liver injury. Phytomedicine, 2023 (PubMed: 36343550) [IF=6.7]

6). Buqi Huoxue Tongnao prescription protects against chronic cerebral hypoperfusion via regulating PI3K/AKT and LXRα/CYP7A1 signaling pathways. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024 (PubMed: 38959552) [IF=6.7]

7). Oleanolic acid alleviates ANIT-induced cholestatic liver injury by activating Fxr and Nrf2 pathways to ameliorate disordered bile acids homeostasis. PHYTOMEDICINE, 2022 (PubMed: 35605478) [IF=6.7]

8). Targeting mTOR/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation. Phytomedicine, 2023 (PubMed: 36889164) [IF=6.7]

9). miR-182-5p promotes hepatocyte-stellate cell crosstalk to facilitate liver regeneration. Communications Biology, 2022 (PubMed: 35915318) [IF=5.9]

Application: WB    Species: Mouse    Sample: liver

Fig. 7 Hepatic miR-182-5p targets Cyp7a1 to promote hepatocyte proliferation. a The heatmap of DEGs in BA synthesis signaling pathway. Green represents downregulation while red represents up regulation. qRT-PCR analyses of Cyp7a1 and Cyp27a1 gene expression in the liver of miR-182-5p KO (b) or TG mice (c) compared with their respective control mice (3d after PH; n = 4/group). miR-182-5p mimic (182 m) or its negative control (ncm) were overexpressed in primary hepatocytes from C57BL/6 J mice. d, e miR-182-5p level, and the Cyp7a1 and Cyp27a1 genes expression levels were determined by qRT-PCR (n = 5/group). f The Cyp7a1 protein expression level was determined by western blot. g Alignment of the sequences of Cyp7a1 gene promoter and miR-182-5p. h Luciferase reporter assay to examine the interactions between miR-182-5p and the predicted target site in the Cyp7a1 gene promoter. Plasmids with the Cyp7a1 gene promoter or mutated gene promoter were co-transfected with miR-182-5p mimic or control mimic into primary hepatocytes. Renilla luciferase activity was measured by a Dual-Glo luciferase assay system and normalized to internal control firefly luciferase activity (n = 3 biological Replicates). HSCs co-cultured with Cyp7a1 siRNA (HepCyp7a1-siRNA) or their control siRNA-treated (HepNC-siRNA) hepatocytes isolated from TG mice. i, j qRT-PCR analyses of α-SMA and Ihh genes expression in HSCs. k qRT-PCR analyses of Cyclin genes expression in primary hepatocytes. l EdU immunostaining of primary hepatocytes. m A proposed model on the mechanism by which miR-182-5p regulates liver regeneration induced by PH. Error bars in all experiments represent SEM; Significance was determined by unpaired two-tailed Student’s t test and by one-way ANOVA.

10). Polygoni Multiflori Radix interferes with bile acid metabolism homeostasis by inhibiting Fxr transcription, leading to cholestasis. Frontiers in pharmacology, 2023 (PubMed: 36950015) [IF=5.6]

加载更多

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.